Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT
HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first…
0,085€
0,71%
Echtzeit-Aktienkurs HOFSETH BIOCARE NK 0,01
Bid:
Ask:
Nachrichten zur HOFSETH BIOCARE NK 0,01 Aktie
Hofseth Biocare ASA: CFO RESIGNATION
Christel Elise Kanli has decided to step down as Chief Financial Officer (CFO) of Hofseth BioCare ASA (“HBC”) to pursue…
Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT
Ålesund, Norway, 8 October 2024.…
Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT
HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half…
Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.
Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces…
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an…
Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT
The first quarter of 2024 continued on the positive trend for HBC. Sales revenues came in at NOK 52m vs…
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the companys premises at Keiser Wilhelms…
Hofseth Biocare ASA: HBC ANNUAL REPORT 2023
The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2023 and the Company has today…
Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING
Today, 5 April 2024, funds managed by Bonafide (Bonafide Global Fish Fund, Bonafide Best Catches I, HBC I, and HBC…
Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT
HBC had gross operating revenues of NOK 47.4m (33.6m) in the fourth quarter and NOK 218.5m (120.4m) for the full…
Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity
HBC Immunology Inc. (70.6% owned by Hofseth BioCare ASA) reports today the successful completion of the first in vivo study…
Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
Reference is made to the stock exchange announcement on 4 January 2024 regarding the conclusion of an extraordinary general meeting…
Hofseth Biocare ASA: EXTRAORDINARY GENERAL MEETING CONCLUDED
Hofseth Biocare ASA ("HBC" or the "Company") has today, on 4 January 2024, completed an extraordinary general meeting. All items…
Hofseth Biocare ASA: EGM Notice Correction
Reference is made to the stock exchange notice announced by Hofseth Biocare ASA ("HBC" or the "Company") on 14 December…
Hofseth Biocare ASA: Notice of an extraordinary general meeting
Reference is made to the stock exchange notice announced by Hofseth Biocare ASA ("HBC" or the "Company") on 13 December…
Hofseth Biocare ASA: SIGNIFICANT NEW INVESTMENT OF NOK 144 MILLION FROM HOFSETH INTERNATIONAL INTO HBC
The board of directors (the “Board”) of Hofseth BioCare ASA ("HBC" or the "Company") has reached an agreement with Hofseth…
Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act…
Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE
Hofseth International AS, a close associate of Board member Roger Hofseth, has today agreed to acquire 435,207 shares in Hofseth…
Hofseth Biocare ASA: THIRD QUARTER 2023 FINANCIAL REPORT
The third quarter of 2023 shows a significant growth of forty percent in sales compared to the same period last…
Hofseth Biocare ASA: SECOND QUARTER 2023 FINANCIAL REPORT
The second quarter of 2023 shows a 100 % growth in sales compared to the same period last year and…
Hofseth Biocare ASA: SUCCESSFULLY COMPLETED SEED ROUND CAPITAL RAISE IN HBC IMMUNOLOGY LLC AT $20M VALUATION FOR THE DEVELOPMENT OF A NEW PROSTATE CANCER CO-THERAPY
HBC Immunology LLC (“HBCI” or the “Company”), a majority owned subsidiary of Hofseth BioCare ASA (“HBC”), has successfully completed the required…
Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
Christel Elise Kanli, primary insider and CFO/COO in Hofseth BioCare ASA («HBC») has today purchased 74,000 shares in HBC at…
Hofseth Biocare ASA: ADVANCING THE TREATMENT OF PROSTATE CANCER WITH PUBLICATION OF FTH1 RESEARCH ABSTRACT AHEAD OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING
HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen…
Hofseth Biocare ASA: SPIN-OFF OF PROSTATE CANCER CO-TREATMENT PROJECT
Hofseth Biocare ASA ("HBC" or the "Company") today announces the decision to transfer its prostate cancer co-treatment project (the "Project")…
Hofseth BioCare ASA: FIRST QUARTER 2023 FINANCIAL REPORT
The first quarter of 2023 shows a very good development for HBC. Revenues came in at NOK 44m vs NOK…
Hofseth Biocare ASA: COMPLETED ANNUAL GENERAL MEETING
Hofseth BioCare ASA held its Annual General Meeting on 28 April 2023. 253,351,609 shares, amounting to 64.13 per cent of…
Hofseth Biocare ASA: DISCLOSURE OF VOTING PROXIES
Reference is made to the notice from Hofseth BioCare ASA (the "Company") for an annual general meeting to be held…
Hofseth Biocare ASA: HBC ANNUAL REPORT 2022
The Board of Directors of Hofseth BioCare ASA (“HBC”) has approved the financial statements for 2022 and the Company has…
Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare…
Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
Christoph Baldegger, primary insider and member of the board of directors in Hofseth BioCare ASA ("HBC") has today purchased 100,000…
Hofseth Biocare ASA: FOURTH QUARTER 2022 & FULL YEAR FINANCIAL REPORT
In Q4, the ingredients business continued to show favorable momentum with growth of 87 %, compared to same quarter last…
Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE
Ødegård Prosjekt AS, a wholly owned company of Jon Olav Ødegård has today, 30 December 2022, bought 70,000 shares at…
Hofseth Biocare ASA: STANFORD SCHOOL OF MEDICINE SUCCESSFULLY COMPLETES PRE-CLINICAL TRIAL WORK TESTING PROGO® BIOACTIVE PEPTIDES IN EFFECTIVE GUT HEALTH SUPPORT
The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and…